A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
NCT ID: NCT04488016
Last Updated: 2021-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
54 participants
INTERVENTIONAL
2020-06-24
2021-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
NCT04564040
A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers
NCT04435483
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
NCT00849329
Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
NCT04211545
A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
NCT06948006
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The relative bioavailability part of Study Part 1 is designed to investigate the PK of the acalabrutinib tablet compared with the PK of acalabrutinib capsule, when administered as a single dose with water under the fasted condition (\>10 hours). The PPI effect part of Study Part 1 is designed to compare the PK of acalabrutinib tablet with or without coadministration of the PPI rabeprazole. The food-effect part of Study Part 1 is designed to compare the PK of acalabrutinib tablet under fed and fasted conditions. For each subject, a SmartPill will be administered with 120 mL of still water followed immediately by a single oral dose of acalabrutinib tablet (Treatment B, C or D) or acalabrutinib capsule (Treatment A) administered with 120 mL of still water.
Study Part 1 will comprise:
* A screening period of maximum 28 days;
* Three treatment periods during which subjects will be resident from prior to the evening meal the night before dosing with Investigational medicinal product (IMP) (Day -1) until at least 48 hours after dosing; discharged on the morning of Day 3; and
* A Follow-up Visit within 7 to 10 days. There will be a minimum washout period of at least 7 days between each acalabrutinib administration.
A decision to continue with Study Part 2 will be made following a review of the preliminary data for relative bioavailability (acalabrutinib tablet versus acalabrutinib capsule), food effect, PPI effect, and safety observed in Part 1.
Part 2 of this study will be an open-label, 4-treatment-period, 4-treatment, single-center relative bioavailability, randomized crossover study to determine the effect of particle size on the PK of a single dose of acalabrutinib tablet in healthy subjects (males or females).
This relative bioavailability study is designed to investigate the PK of acalabrutinib tablets with various drug substance particle size distributions and the PK of acalabrutinib solution at a single oral dose of 100 mg under the fasted condition (\>10 hours).
Study Part 2 will comprise:
* A screening period of maximum 28 days;
* Four treatment periods during which subjects will be resident prior to the evening meal the night before dosing with IMP (Day -1) until at least 48 hours after dosing; discharged on the morning of Day 3; and
* A Follow-up Visit within 7 to 10 days. There will be a minimum washout period of at least 3 days between each acalabrutinib administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 -Part 1
Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
Treatment A- Part 1
Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Treatment B- Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment C - Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Cohort 2- Part 1
Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
Treatment A- Part 1
Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Treatment B- Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment C - Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Cohort 3- Part 1
Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
Treatment A- Part 1
Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Treatment B- Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment C - Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Treatment D- Part 1
Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
Cohort 4 - Part 1
Subjects will be randomized to one of 4 sequences: ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (\>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (\>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)\* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
Treatment A- Part 1
Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Treatment B- Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment C - Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Treatment D- Part 1
Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
Cohort 1- Part 2
Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC. In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
Treatment A-Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment B - Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
Treatment C - Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
Treatment D - Part 2
Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
Cohort 2 - Part 2
Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC.In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
Treatment A-Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment B - Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
Treatment C - Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
Treatment D - Part 2
Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment A- Part 1
Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Treatment B- Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment C - Part 1
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Treatment D- Part 1
Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
Treatment A-Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Treatment B - Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
Treatment C - Part 2
Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
Treatment D - Part 2
Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy adult male or female subjects aged 18 - 55 years with suitable veins for cannulation or repeated venipuncture.
3. Male subject must adhere to the contraception methods.
4. Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening.
5. Have a Body mass index (BMI) between 18.5 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive at screening.
6. Understands the study procedures in the Informed Consent Form (ICF) and willing and able to comply with the protocol.
7. Willingness and ability to swallow study drugs, including the SmartPill.
8. Willingness to consume a standardized, high- calorie, high-fat FDA breakfast.
Exclusion Criteria
2. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
3. Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections).
4. Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of IMP.
5. Any clinically significant abnormalities in clinical chemistry, hematology, coagulation, or urinalysis results, at screening and first admission to the study unit (first treatment period) as judged by the PI, and defined as: (1) Serum Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and serum bilirubin (total and direct)
\> Upper limit of normal (ULN). (2) Hemoglobin \< ULN.
6. Any clinically significant abnormal findings in vital signs at screening and first admission to the study unit (first treatment period), as judged by the PI.
7. Any clinically significant abnormalities on 12-lead ECG at screening and first admission to the study unit (first treatment period), as judged by the PI.
8. Any positive result on screening for serum hepatitis B surface antigen, hepatitis B core antibody (anti-HBc), hepatitis C antibody, and HIV antibody.
9. Known or suspected history of drug abuse, as judged by the PI.
10. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 90 days of the first administration of IMP in this study.
The period of exclusion begins 90 days after the final dose or 30 days after the last visitwhichever is the longest.
11. Plasma donation within 30 days of screening or any blood donation/loss more than 500 mL during the 90 days prior to screening.
12. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to acalabrutinib or rabeprazole.
13. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 90 days prior to screening.
14. Positive screen for drugs of abuse or cotinine at screening or on each admission to the study center or positive screen for alcohol on each admission to the study center.
15. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
16. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life. Hormone replacement therapy will not be allowed.
17. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
18. Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the PI. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day (e.g., \>5 cups of coffee) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the investigational site.
19. Part 1 only: Inability or unwillingness to swallow SmartPill, including:
Subject has any of the following contraindications for the SmartPill:
1. A history of gastric bezoars
2. Swallowing disorders
3. Suspected or known strictures, fistulas or physiological/mechanical GI obstruction
4. History of GI surgery within 90 days of administration
5. Severe dysphagia to food or pills
6. Crohn's disease or diverticulitis
7. Cardiac pacemakers or other implanted electromedical devices 20 Involvement of any AstraZeneca, Acerta Pharma, Parexel or study site employee or their close relatives. 21 Subjects who have previously received acalabrutinib. 22 Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements. 23 Subjects who cannot communicate reliably with the Investigator. 24 Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acerta Pharma, LLC
OTHER
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald Goldwater,, MD
Role: PRINCIPAL_INVESTIGATOR
PAREXEL Early Phase Clinical Unit Baltimore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D8220C00018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.